RCM
CRXT

Radcliffe Capital Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Radcliffe Capital Management’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-225,000
Closed -$2.27M – 988
2021
Q2 		$2.27M Hold
225,000
– – 0.07% 445
2021
Q1 		$2.27M Buy
+225,000
New +$2.27M 0.09% 391

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Radcliffe Capital Management's CRXT Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2021, closing a stake of 225,000 shares — an estimated $2.27M sold.

Radcliffe Capital Management first reported a position in CRXT in Q1 2021 and held it in 2 quarters. The position peaked at $2.27M in Q2 2021. 12 funds tracked by Wall St. Rank hold CRXT as of Q3 2021.

  • Radcliffe Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 225,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2021, an estimated $2.27M.
  • Radcliffe Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Radcliffe Capital Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $2.27M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.